Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pharmaxis Ltd.
Galecto Validates LOXL2 Targeting With Interim Myelofibrosis Phase II Success
The US biotech’s LOXL2 inhibitor candidate has reduced collagen fibrosis of the bone marrow in a small number of Phase II patients, helping validate a historically tricky approach attempted by few.
COVID-Delayed UK Medtech Mandate Previews First Products For NHS Adoption
The Medtech Mandate, a scheme that seeks to better match NICE guidance with adoption and use of medtech innovations in the UK, is preparing for launch in April.
Keeping Track: Chiesi Breathes Easier With Bronchitol Approval; Submissions Aplenty From GSK, Pfizer, AZ, AbbVie
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
BI Strengthens Research Efforts In IO Stromal Biology And Retinal Disease
Two preclinical antibodies targeted at stromal biology-associated immuno-oncology processes from Canada’s Northern Biologics have been acquired by Boehringer Ingelheim, which is also to collaborate with Switzerland’s CDR-Life on the development of a preclinical antibody fragment aimed at geographic atrophy associated with age-related macular degeneration.
- In Vitro Diagnostics
- Medical Devices
- Drug Delivery
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Topigen Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.